Document is current
Any future updates will be listed below
-
Authors
Westerheim, Ingunn http://orcid.org/0000-0002-2839-9856
Cormier-Daire, Valerie
Gilbert, Scott
O’Malley, Sean
Keen, Richard
-
Funding
Funding for this research was provided by:
Mereo BioPharma (N/A)
- License Information
-
More Information
Article History
Received: 2 April 2024
Accepted: 29 August 2024
First Online: 9 September 2024
Declarations
:
: Ethics approval for the study was not required. Written informed consent was obtained from each patient interviewed for the study.
: Written informed consent was obtained from each patient interviewed for the study.
: IW is President of OIFE, which has received conference grants and donations from Mereo BioPharma, Ultragenyx, Quince Therapeutics, UCB, Angitian Bio, Azafaros, Alexion and Pega Medica and Orthopediatrics. IW is a member of a steering committee at Sanofi and has received speaker funding from Takeda. VCD is the principal investigator in a clinical trial funded by Mereo BioPharma and Ultragenyx. SG and SOM were paid by Mereo Biopharma to complete the market research used in this publication. RK is a consultant for Mereo Biopharma and has a voluntary (unpaid) role as the Chair of the Brittle Bone Society Scientific Committee, Dundee, UK. IW, VCD and RK received no specific payment associated with the development of this manuscript.
